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Perinatal transmission of hepatitis B virus (HBV) and its associated immune escape mutants (IEMs), is the major vehicle
through which a population of chronically infected people who serve as infectious HBV reservoirs is maintained in
communities. Therefore, to assess the risk of perinatal transmission, 272 pregnant women attending ante-natal
clinics in Ibadan metropolis, southwestern, Nigeria, were screened for HBsAg using ELISA technique. Samples
positive for HBsAg were subjected to HBV DNA detection by PCR amplification of the S-gene and amplicon
sequencing. Isolates were genotyped and subtyped using a combination of molecular techniques.
Fifteen (5.5%) of the pregnant women were positive for HBsAg of which HBV DNA was detected in seven.
Five of the isolates were typed as genotype E subtype ayw4 using amino acid residues at positions 122, 127,
134 and 160. Another could only be typed as genotype E subtype ayw4 by further phylogenetic analysis. The
remaining one isolate did not belong to any of genotypes A – H. Three of the HBV isolates including the
untypable, had mutations in the ‘a’ determinant associated with IEMs.
This study confirms the endemicity of HBV, the risk of perinatal transmission and the circulation of genotype
E subtype ayw4 in Nigeria. It further demonstrates the presence of IEMs in Nigeria.
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Hepatitis B virus (HBV) belongs to the genus orthohepad-
navirus in the family Hepadnaviridae. HBV is an enveloped
virus with a diameter of ~42 nm. Within the core of the
virus is a protein-linked, ~3.2 kb DNA genome that is
partly double stranded. The HBV genome has four open
reading frames (ORFs) (X, S, P and C) with the X and C
ORFs partially overlapping the P ORF which also has the S
ORF within it but in a different reading frame. Genotypes
A - H of HBV have been described (Schaefer 2007) with
members of a genotype not differing by more than 8% of
their genome (Okamoto et al. 1988). Sub-genotypes have* Correspondence: adewumi1@hotmail.com
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in any medium, provided the original work is palso been described with members not differing by more
than 4% of their genome (Norder et al. 2004).
Hepatitis B virus (HBV) infection is one of the top 10
viral infections globally (Perz et al. 2006). Serologic evi-
dence of past or present HBV infection has been shown
in approximately one-third of the world’s population
(i.e., over 2 billion people) (World Health Organization
2009). Infection with HBV could result in outcomes ran-
ging from an acute, self-limiting disease through chronic
hepatitis B (CHB) to cirrhosis and hepatocellular carcin-
oma (HCC) (Gerlich 2013). Furthermore, about 360 mil-
lion people globally are chronically infected with HBV
(World Health Organization 2009).
About 90% of children who get infected perinatally be-
come chronic HBV carriers (Beasley et al. 1981; Chang
2007). Hence, vertical transmission of HBV is a majorn Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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maintained in populations (Beasley et al. 1981; Chang
2007). This can and is being addressed by identifying
and treating HBV infected pregnant women and admin-
istering both passive (Beasley et al. 1981) and active
(Poovorawan et al. 1989; Lavanchy 2012) immunization
to their offspring at birth. However, there have been
cases in which children or adults who have been vacci-
nated against HBV and have serologic correlates of HBV
immunity get re-infected with HBV (Carman et al. 1990;
Harrison et al. 1991; Fujii et al. 1992; Theamboonlers
et al. 2001). The HBV isolates recovered from such cases
are usually referred to as Immune Escape Mutants (IEMs)
(Carman et al. 1990; Lada et al. 2006; Ramezani et al. 2013).
Immune escape mutants (IEMs) were first described in
Italy in 1990 (Carman et al. 1990). The development of
IEMs has been ascribed to the fact that HBV has both
an RNA phase in its replication cycle and a polymerase
without ‘proof-reading’ ability, and as such has an error
rate that is close to that of RNA viruses (Orito et al.
1989; Mizokami and Orito 1999). Consequently, mutants
develop spontaneously and can be selected for by anti-
HBs and the use of nucleoside/nucleotide analogue clas-
ses of antiviral drugs (Cento et al. 2013).
Several studies have reported the presence and circula-
tion of IEMs (Carman et al. 1990; Harrison et al. 1991;
Fujii et al. 1992; Theamboonlers et al. 2001; Forbi et al.
2013) but not in Nigeria. Since HBV vaccination was
added to the National Immunization programme over
ten years ago (WHO 2005a; Sadoh and Eregie 2008) and
nucleoside/nucleotide analogue classes of antiviral drugs
are being used by the HIV and/or HBV infected popula-
tion in the country (WHO 2005b), this study was designed
to investigate the possible emergence and circulation of
IEMs in pregnant women in Nigeria. Here we report, for
the first time, the presence of HBV IEMs in Nigeria.
Material and methods
Study location
This study was carried out among pregnant women
attending two different ante-natal clinics in Ibadan,
southwestern Nigeria. The two hospitals were selected to
facilitate true representation of the population in the study.
The first being the University College Hospital (UCH); a
tertiary health care facility of the University of Ibadan. The
second hospital is Ade-Oyo State Hospital (ASH); a sec-
ondary health care facility located in a central, densely pop-
ulated part of the city. Attendees in both ante-natal clinics
are majorly residents in the city.
Enrolment of patients
Consenting ante-natal clinic attendees were enrolled from
the two selected hospitals described above. Enrolment
took place between September 2012 and June, 2013.During the period, a total of 813 and 1686 ante-natal
clinic attendees were enrolled at the ASH and UCH re-
spectively. Short presentation on HBV prevalence and
prevention was given during each visit to the ante-
natal clinics. Thereafter, consenting clinic attendees
were enrolled for the study. Demographic and other
relevant information were retrieved from the study partici-
pants using a structured questionnaire. Afterwards, blood
sample was collected from each of the 272 {median age =
31.07 years, age range = 17–43 years (NGRAD: n = 90; age
range = 19–42 years; NGRUC: n = 182; age range = 17–43
years)} consenting subjects enrolled at the point of
registration and routine examination for ante-natal
clinic. Ethical approvals for the study were granted by the
UI/UCH Ethics Committee (UI/EC/11/0058) and Min-
istry of Health (AD3/479/349).
Sample collection
Five milliliters of blood was collected from each pregnant
woman by venepuncture. The blood sample was then dis-
pensed into an appropriately labeled sterile container
without any preservative or anticoagulant. Subsequently,
the samples were transported to the laboratory at about
4-8°C in a cooler with frozen ice packs. Serum was sepa-
rated from other blood components by low-speed centrifu-
gation at 500 g for 5 minutes and subsequently removed
using a sterile disposable pipette. Two aliquots of serum
were made per sample in labeled sterile cryovials which
were stored at −20°C until ready for analysis. Laboratory
analysis was carried out in the Department of Virology, and
the Institute for Advanced Medical Research and Training,
College of Medicine, University of Ibadan, Ibadan, Nigeria.
HBsAg ELISA screen
All the 272 samples were subjected to HBsAg specific
Enzyme Linked Immunosorbent Assay (ELISA) using
the HBsAg detection ELISA kit (Diagnostic Automation/
Cortez Diagnostic, California, USA). The assay was per-
formed according to manufacturer’s instructions. The
optical density was read using the Emax endpoint ELISA
microplate reader (Molecular Devices, California, USA)
and the result was interpreted according to the manufac-
turer’s instructions.
DNA extraction and HBsAg specific Polymerase Chain
Reaction (PCR)
DNA was extracted using the QIAGEN DNA extraction
kit (Qiagen, Hilden, Germany) according to the manu-
facturer’s instructions. Subsequently, a nested PCR assay
targeting a ~408 bp stretch within the S ORF was used
to detect HBV DNA. First round primers were HBV_S1F
5-CTAGGACCCCTGCTCGTGTT-3, and HBV_S1R 5-
CGAACCACTGAACAAATGGCACT-3, while second
round primers were HBV_SNF 5-GTTGACAAGAATCC
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CCATA-3 (Forbi et al. 2013). Primers were made in
25 μM concentrations and two microliter of each of the
primers was added to a 50 μL reaction containing 10 μL
of Red load Taq (Jena Bioscience, Jena, Germany), 4 μL
of DNA and 32 μL of RNase free water. Thermal cycling
was done in a Veriti Thermalcycler (Applied Biosystems,
California, USA.) as follows; 94°C for 3 minutes followed
by 45 cycles of 94°C for 30 seconds, 55°C for 60 seconds
and 70°C for 40 seconds with ramp of 40% from 55°C to
70°C. This was then followed by 72°C for 7 minutes and
held at 4°C till terminated. Reaction conditions were the
same for both first and second round PCR except that
DNA extract from the sample was used as template for
first round PCR while first round PCR product was used
as template for second round PCR. Finally, PCR prod-
ucts were resolved on 2% agarose gels stained with eth-
idium bromide and viewed using a UV transilluminator.
Amplicon sequencing
The PCR reactions that were positive by having the re-
quired amplicon size were shipped to Macrogen Inc, Seoul,
South Korea, for amplicon purification and BigDye chem-
istry sequencing. Sequencing was done using primers
HBV_SNF and HBV_SNR.
Phylogenetic analysis
Amino acid residues at positions 122, 127, 134 and 160
were initially used to determine HBV genotypes and
serotypes (Forbi et al. 2013). Subsequently, HBsAg refer-
ence sequences were retrieved from the HBV database
(http://hbvdb.ibcp.fr/HBVdb/) and aligned using the
CLUSTAL W program in MEGA 5 software with de-
fault settings (Tamura et al. 2011). Afterwards, a neighbor-
joining tree was constructed using MEGA 5 software with
the Kimura-2 parameter model (Kimura 1980) and 1,000
bootstrap replicates. Furthermore, pairwise distance of the
HBsAg sequences were estimated using MEGA 5 software
with Kimura-2 parameter model (Kimura 1980). The
accession numbers of sequences retrieved from HBVTable 1 Serotype and genotype of sequenced HBV isolates
S/N Sample ID Amino acid residues at posit
surface antigen for serotype
s122 s127
1 NGRAD-13-065-A4-HBsAg R L
2 NGRUC-12-054-A8-HBsAg Q L
3 NGRUC-13-008-B2-HBsAg R L
4 NGRUC-13-045-M8-HBsAg R L
5 NGRUC-13-078-B6-HBsAg R L
6 NGRUC-13-084-B7-HBsAg R L
7 NGRUC-13-100-C1-HBsAg R Ldatabase for phylogenetic analysis are indicated in the
sequence names on the phylograms.
Nucleotide sequence accession numbers
The sequences reported in this study have been submitted
to GenBank Nucleotide Sequence Database under the ac-
cession numbers KM225621 - KM225627.
Results
HBsAg ELISA screen, DNA extraction and Surface/Pol
gene specific Polymerase Chain Reaction
A total of 15 (5.5%) of the 272 samples were positive for
HBsAg. DNA was extracted from all the 15 samples that
were positive for the HBsAg ELISA screen, and subjected
to HBsAg specific PCR. Despite repeated attempts
the ~408 bp amplicon within the S ORF was successfully
amplified in only 7 (46.7%) of the 15 HBsAg positive
samples.
Phylogenetic analysis
Based on the amino acid residues at positions s122,
s127, s134 and s160 (Forbi et al. 2013), five of the seven
sequenced isolates belonged to genotype E and serotype
ayw4 (Table 1). The remaining two HBV isolates could
not be typed using this classification scheme because
isolate NGRUC-12-054-A8-HBsAg had sR122Q substitu-
tion and isolate NGRUC-13-100-C1-HBsAg had sF134V
substitution (Figure 1). To classify the two untypable HBV
isolates, a phylogram was constructed using the sequences
isolated in this study alongside reference HBV sequences
of genotypes A–H from the HBV database (http://hbvdb.
ibcp.fr/HBVdb/). The phylogram (Figure 2) showed that,
just like the previously classified five isolates, isolate
NGRUC-13-100-C1-HBsAg belonged to genotype E,
ayw4. Furthermore, isolate NGRUC-13-100-C1-HBsAg is
only 1.1% divergent (Table 2) from a reference genotype E,
ayw4 strain (AB091255). Hence, confirming its member-
ship in this group.
The phylogram (Figure 2) also showed that isolate




F K ayw4 E
F K Untypable Untypable
F K ayw4 E
F K ayw4 E
F K ayw4 E
F K ayw4 E
V K Untypable Untypable
Figure 1 Alignment of amino acid residues of the seven isolates sequenced in this study against a reference genotype E strain. Of
particular interest are isolates NGRUC-12-054-A8-HBsAg, NGRUC-13-084-B7-HBsAg and NGRUC-13-100-C1-HBsAg with mutations in the ‘a’
determinant (s122 to s160).
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Similarity matrix (Table 3) also showed that it is between
12.0 and 18.9% divergent from genotypes A – H and as
such does not belong to any of the genotypes. It is how-
ever most closely related to genotype E at 12.0%. The
Major Hydrophilic Region (MHR; s122 – s160) of isolate
NGRUC-12-054-A8-HBsAg showed an abundance of
substitutions which included; sG112K, sG119K, sR122Q,
sC124Y, sA128T, sG130K, sM133T, sC138Y, sG145K,
sC147Y, sC149Y, sA157T and sG159K (Figure 1).
Other isolates asides NGRUC-12-054-A8-HBsAg also
have significant substitutions within the MHR. These in-
cluded, isolates NGRUC-13-084-B7-HBsAg (sC138S and
sG159R) and NGRUC-13-100-C1-HBsAg (sF134V and
sS140L) (Figure 1).
Discussion
Mutations in the S gene and vaccine escape mutants
The results of this study showed the presence of G145K
in one of the HBV isolates (NGRUC-12-054-A8-HBsAg)
detected. This substitution alongside G145R have been
associated with immune escape mutants (IEMs) (Carman
et al. 1990, 1995; Karthigesu et al. 1994; Grethe et al.
1998; Lada et al. 2006). This study therefore reports for
the first time the presence of IEMs in Nigeria and particu-
larly in a pregnant woman.
Asides the G145K substitution, NGRUC-12-054-A8-
HBsAg had other substitutions that might work syner-
gistically to enhance the immune escape phenotype pre-
dicted. For example, the substitution of cysteine residues at
positions s124, s138, s147 and s149 with tyrosine (Figure 1)
will abolish the formation of the disulphide bondspredicted to stabilise the double-loop structure of the
HBsAg extravirion region (Prange and Streeck 1995). In-
silico structure prediction studies (unpublished data) sug-
gested that the three dimensional conformation of the
extravirion loop of this isolate is different from that of
the wild-type genotype E, ayw4 isolate. In addition, instead
of being extravirion, the loop is embedded in the polar
head-groups of the extravirion leaflet of the virion mem-
brane. This buttresses the fact that this isolate might in-
deed be an IEM. Similar structural prediction results were
obtained for isolates NGRUC-13-084-B7-HBsAg and
NGRUC-13-100-C1-HBsAg which also have substitutions
between residues s133 and s144 (unpublished data).
The results of this study showed that 3 out of the 7
isolates (NGRUC-12-054-A8-HBsAg, NGRUC-13-084-
B7-HBsAg and NGRUC-13-100-C1-HBsAg) sequenced
in this study had mutations that have been associated
with immune escape mutants (IEMs) (Carman et al.
1990, 1995; Karthigesu et al. 1994; Grethe et al. 1998;
Lada et al. 2006; Forbi et al. 2013). This may imply con-
siderable rate of IEM emergence. However, the eco-
logical system necessary to create the adequate amount
of evolutionary pressure necessary to select for HBV IEMs
at such high rate is present in Nigeria. Factors necessary
to provide such selective pressure include spontaneous er-
rors by HBV polymerase, the host immune response to
natural HBV infection, active and passive immunization,
and use of nucleoside/nucleotide analogue antiviral drugs
by HIV and/or HBV infected individuals (Cento et al.
2013). The first two factors are intrinsic to HBV and
humans, and are consequently always present while, the
last two have been in place in Nigeria for over ten years
Figure 2 Phylogenetic relationship of recovered HBV isolates. The phylogram is based on an alignment of the partial HBsAg sequences. The
newly sequenced strains are highlighted with black circle, while a genotype E reference strain is highlighted with a black triangle. The GenBank
accession number of the strains are indicated in the tree. Bootstrap values are indicated if ≥ 70%.
Faleye et al. SpringerPlus  (2015) 4:43 Page 5 of 8
Table 2 Comparison of reference sequences gnl|hbvcds|AB091255 genotype E to all isolates recovered in this study
Species 1 Species 2 Dist % Siml %
gnl|hbvcds|AB091255 REFERENCE BACKBONE genotype E NGRAD-13-065 A4 HBsAg 0.8 99.2
gnl|hbvcds|AB091255 REFERENCE BACKBONE genotype E NGRUC-12-054 A8 HBsAg 12.5 87.5
gnl|hbvcds|AB091255 REFERENCE BACKBONE genotype E NGRUC-13-008 B2 HBsAg 1.1 98.9
gnl|hbvcds|AB091255 REFERENCE BACKBONE genotype E NGRUC-13-045 M8 HBsAg 1.1 98.9
gnl|hbvcds|AB091255 REFERENCE BACKBONE genotype E NRGUC-13-078 B6 HBsAg 1.1 98.9
gnl|hbvcds|AB091255 REFERENCE BACKBONE genotype E NGRUC-13-084 B7 HBsAg 1.6 98.4
gnl|hbvcds|AB091255 REFERENCE BACKBONE genotype E NGRUC-13-100 C1 HBsAg 1.1 98.9
gnl|hbvcds|AB091255 REFERENCE BACKBONE genotype E gnl|hbvcds|AB091260 genotype E 0.5 99.5
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shows that the conditions had always been present for
HBV IEMs to emerge.
The HBV IEMs characterized in this study did not
share mutations in the ‘a’ determinant (Figure 1). This
shows that the IEMs must have emerged as a result of
independent events. This finding has two implications.
Firstly, it corroborates the fact that the conditions were
perfect for HBV IEM emergence in Nigeria, and sec-
ondly, it shows that HBV immune escape mutants can
evolve over a sequence and conformational space.Table 3 Comparison of isolate NGRUC-12-054 A8 HBsAg to al
from genotypes A to H
Species 1 Species 2
NGRUC-12-054 A8 HbsAg NGRUC-13-008 B2 HBsAg
NGRUC-12-054 A8 HbsAg NGRUC-13-045 M8 HBsAg
NGRUC-12-054 A8 HbsAg NRGUC-13-078 B6 HBsAg
NGRUC-12-054 A8 HbsAg NGRUC-13-084 B7 HBsAg
NGRUC-12-054 A8 HbsAg NGRUC-13-100 C1 HBsAg
NGRUC-12-054 A8 HbsAg gnl|hbvcds|AB116085 genotype A
NGRUC-12-054 A8 HbsAg gnl|hbvcds|AB116086 genotype A
NGRUC-12-054 A8 HbsAg gnl|hbvcds|AB031266 genotype B
NGRUC-12-054 A8 HbsAg gnl|hbvcds|AB031267 genotype B
NGRUC-12-054 A8 HbsAg gnl|hbvcds|AB014364 genotype C
NGRUC-12-054 A8 HbsAg gnl|hbvcds|AB014365 genotype C
NGRUC-12-054 A8 HbsAg gnl|hbvcds|AB090268 genotype D
NGRUC-12-054 A8 HbsAg gnl|hbvcds|AB090269 genotype D
NGRUC-12-054 A8 HbsAg gnl|hbvcds|AB091260 genotype E
NGRUC-12-054 A8 HbsAg gnl|hbvcds|AB036912 genotype F
NGRUC-12-054 A8 HbsAg gnl|hbvcds|AB036913 genotype F
NGRUC-12-054 A8 HbsAg gnl|hbvcds|AB064310 genotype G
NGRUC-12-054 A8 HbsAg gnl|hbvcds|AB064311 genotype G
NGRUC-12-054 A8 HbsAg gnl|hbvcds|AB179747 genotype H
NGRUC-12-054 A8 HbsAg gnl|hbvcds|AB205010 genotype H
NGRUC-12-054 A8 HbsAg NGRAD-12-065 A4 HBsAg
NGRUC-12-054 A8 HbsAg Gnl|hbvcds|AB091255 reference bHowever, as a result of the small number of isolates re-
covered in this study, it is difficult to extrapolate as
regards the circulation of these mutants. What is obvi-
ous is that the results of this study do not provide evi-
dence to support circulation of these mutants in the
region and this is corroborated by the fact that none of
the previous studies in the region ever reported detec-
tion of HBV IEMs (Odemuyiwa et al. 2001; Forbi et al.
2010).
It is pertinent to note that, despite repeated attempts
the ~408 bp amplicon within the S ORF could not bel isolates recovered in this study and reference sequences
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This could be due to low viral load, primer mismatch as
a result of point mutations or virus strains being of re-
combinant origin. However, effort is underway to further
characterize the isolates using sequence independent
strategies.
HBV genotypes circulating in Nigeria and the
classification scheme
The circulation in Nigeria of HBV genotype E, serotype
ayw4 was documented in this study. This confirms pre-
vious reports (Odemuyiwa et al. 2001; Forbi et al. 2010).
Furthermore, the findings of this study confirm the in-
clusion of Nigeria in the HBV genotype E crescent as
previously described (Odemuyiwa et al. 2001; Mulders
et al. 2004; Olinger et al. 2006; Andernach et al. 2009;
Forbi et al. 2010). However, the use of amino acid residues
at positions s122, s127, s134 and s160, though useful for
classifying HBV isolates, obviously has its limitations. For
example, of the six HBV genotype E, serotype ayw4 iso-
lates sequenced in this study, five could be typed as such
using this algorithm. This algorithm failed to identify the
last isolate because of an sF134V substitution. Had it not
been for phylograms and similarity matrices one of the
isolates would have gone untyped. It might therefore be
necessary to combine methods when identifying HBV iso-
lates. Also, the inclusion of valine as one of the amino acid
residues that could be present at position 134 of HBV
genotype E, ayw4 should be considered.
HBsAg prevalence in pregnant women
In this study, HBsAg prevalence of 5.5% was observed
among pregnant women in southwestern Nigeria. This is
similar to a prevalence of 6% found in south-south
Nigeria (Alegbeleye et al. 2013) but different from higher
prevalence (>8%) reported in other parts of the country
(Ndams et al. 2008; Olokoba et al. 2011). The reasons
for this variation is not clear, though several reasons
have been suggested (Alegbeleye et al. 2013). Given
HBsAg prevalence of 5.5% (as the lower limit) among
pregnant women in Nigeria, an annual birth cohort of
7,310,490 in Nigeria (Gavi Alliance 2014), and a <5% risk
of developing CHB in children that acquire HBV peri-
natally from HBsAg positive but HBeAg negative
mothers (Hsu et al. 2004; Chang 2007). This implies that
about 20,104 children on the average might be develop-
ing CHB annually in Nigeria.
As observed in Taiwan (Su et al. 2012) and Thailand
(Poovorawan et al. 2011), with the incorporation of HBV
vaccine into the National Immunization Programme and
significant vaccine coverage, the number of children devel-
oping CHB annually should reduce to about 0.5% (i.e.,101
CHB children in Nigeria) of the estimated present value in
about two decades. However, in Nigeria, though HBVvaccine is administered at birth in tertiary health care fa-
cilities, the same cannot be said of secondary and primary
health care facilities. Consequently, reduction in the num-
ber of children estimated to develop CHB to about 0.5% of
the exposed may not have been achieved in the country.
Though, the possibility of achieving the above stated still
exist, since the country still has about a decade (WHO
2005a; Sadoh and Eregie 2008) to attain comparable
situation with Taiwan (Su et al. 2012) and Thailand
(Poovorawan et al. 2011).
Even if the National Immunization Programme in
Nigeria achieves the reduction in estimated number of
children developing CHB to 0.5% of the exposed, the
presence of HBV IEMs and probable perinatal transmis-
sion to about 6.7% (one IEM out of 15 HBsAg positive; a
lower limit of this study) of the perinatally exposed
might undermine the impact of the vaccination effort by
the immunization being ineffective in ~1347 children.
This might result in the development of a cohort of
CHB children that may serve as reservoirs for the main-
tenance of HBV, and specifically HBV IEMs in the
population.
Conclusion
The results of this study showed, for the first time in
Nigeria, the presence of HBV isolates with mutations
that have been associated with immune escape mutants.
The results also confirmed circulation of HBV IEMs
among pregnant women in Nigeria.
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